Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Immunotherapy

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen

Front Immunol.

Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S

doi: 10.3389/fimmu.2019.01613.

Immunotherapy

The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia

Ann Pharmacother.

Horvat TZ, Seddon AN, Ogunniyi A, King AC, Buie LW, Daley RJ

doi: 10.1177/

Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma

Curr Res Transl Med.

Ghobadi A

doi: 10.1016/

T Cells

Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?

Lancet Haematol

Gudiol C, Lewis RE, Strati P, Kontoyiannis DP

doi: 10.1016/S2352-3026(20)30376-8

Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation

PLoS One.

Koparde V, Abdul Razzaq B, Suntum T, Sabo R, Scalora A, Serrano M, Jameson-Lee M, Hall C, Kobulnicky D, Sheth N, Feltz J, Contaifer D Jr, Wijesinghe D, Reed J, Roberts C, Qayyum R, Buck G, Neale M, Toor A

doi: 10.1371/

T CellsImmune Response

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

J Clin Oncol

Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M

doi: 10.1200/JCO.21.01992

T Cells

The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway

Clin Immunol.

Rodríguez-Rodríguez N, Madera-Salcedo IK, Bugarin-Estrada E, Sánchez-Miranda E, Torres-García D, Cervantes-Torres J, Fragoso G, Rosetti F, Crispín JC, Sciutto E

doi: 10.1016/j.clim.

Further Publications Dermatology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ, Oxford COVID Vaccine Trial Group.

doi: 10.1016/S0140-6736(20)32466-1

Further Publications Rheumatology

Activated peripheral blood B cells in rheumatoid arthritis and relationship to anti-TNF treatment and response: randomized clinical trial for anti-TNF effects on B cells

Arthritis Rheumatol

Meednu N, Barnard J, Callahan K, Coca A, Marston B, Thiele R, Tabechian D, Bolster M, Curtis J, Mackay M, Graf J, Keating R, Smith E, Boyle K, Keyes-Elstein L, Welch B, Goldmuntz E, Anolik JH

doi: 10.1002/art.41941

Related content